Patents

US 9486484 B2: Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease

Granted
2016-11-08
Filed
2014-07-21 application 14336755
Type
Utility · 20 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and/or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration.

Source: PVGPATDIS, file of 2026-04-10 (ipg161108.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
CYTORI THERAPEUTICS, INC. 21 patentsUS company or organizationSan Diego, CACYTORI THERAPEUTICS, INC. State business registration EXACT high confidence: identical full name and statePVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Zeni AlfonsoTemecula, CA2PVGPATDIS, file of 2026-04-10
John K. FraserSan Diego, CA21PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
C12NMicroorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture mediaC12N5/0651PVGPATDIS, file of 2026-04-10
A61KPreparations for medical, dental or toiletry purposesA61K35/28PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P3/06PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2019-08-01Correction
Corrective assignment to correct the correct assignee's address previously recorded at reel: 049313 frame: 0434. assignor(s) hereby confirms the assignment.
CYTORI THERAPEUTICS, INC. signed 2019-04-24LOREM VASCULAR PTE. LTD. SINGAPORE49942/204ECORSEXC, file of 2026-09-25
2019-05-17Assignment
Assignment of assignor's interest
CYTORI THERAPEUTICS, INC. signed 2019-04-24LOREM VASCULAR PTE. LTD. MELBOURNE VIC49313/434ECORSEXC, file of 2026-09-25
2019-04-25Assignment
Assignment of assignor's interest
CYTORI THERAPEUTICS, INC. signed 2019-04-24LOREM VASCULAR PTE. LTD. SAN DIEGO, CA49651/1ECORSEXC, file of 2026-09-25
2019-04-25Release of security interest
Release of security interest
OXFORD FINANCE LLC signed 2019-04-23CYTORI THERAPEUTICS, INC. SAN DIEGO, CA49011/347ECORSEXC, file of 2026-09-25
2017-09-22Security interest Security interest
Security interest
CYTORI THERAPEUTICS, INC. signed 2017-09-20OXFORD FINANCE LLC, AS COLLATERAL AGENT ALEXANDRIA, VA43952/150ECORSEXC, file of 2026-09-25
2014-09-03Assignment
Assignment of assignor's interest
ALFONSO, ZENI signed 2014-08-12
FRASER, JOHN K. signed 2014-08-12
CYTORI THERAPEUTICS, INC. SAN DIEGO, CA33660/917ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.